Answers are grounded in this paper and cite their sources.
Background Platelet-rich plasma (PRP) is used as an orthobiologic injection therapy for knee osteoarthritis (OA), but reported outcomes vary according to PRP formulation, injection protocol, comparator, and patient selection. Real-world data describing the Zimmer Biomet GPS leukocyte-rich PRP system in Japanese clinical practice remain limited. Purpose To describe 1-year patient-reported outcomes after a single intra-articular GPS leukocyte-rich PRP injection in patients with Kellgren-Lawrence (KL) grade II or III knee OA. Methods This retrospective single-center case series included patients with symptomatic Kellgren-Lawrence (KL) grade II or III knee osteoarthritis (OA) who underwent GPS leukocyte-rich platelet-rich plasma (PRP) injection. During the study period, 20 patients/knees received an initial GPS L-PRP injection; 5 could not be followed at 1 year and were excluded from the paired 1-year analysis. The final analysis included 15 knees with paired baseline and 1-year numeric rating scale (NRS) pain data. Radiography and magnetic resonance imaging were used to support baseline diagnosis and eligibility; MRI was not analyzed as a longitudinal structural outcome. The primary outcome was change in NRS pain. Secondary outcomes included Knee injury and Osteoarthritis Outcome Score (KOOS), Locomo-25, responder status, and adverse events. Results Of 20 patients/knees treated with an initial GPS L-PRP injection, 5 were lost to 1-year follow-up or had unavailable 1-year outcome data; 15 knees from 5 male and 10 female patients were included in the final paired analysis. NRS pain improved from 4.6 ± 2.4 at baseline to 2.7 ± 2.1 at 1 year (mean change, -1.9 points; 95% CI, -3.4 to -0.4; P = 0.015). KOOS quality of life improved from 30.0 ± 17.1 to 45.4 ± 23.8 (mean change, 15.4 points; 95% CI, 4.8 to 26.0; P = 0.010). Other KOOS domains and Locomo-25 showed numerical improvement but did not reach statistical significance. A ≥30% NRS pain reduction occurred in 7 of 15 knees (46.7%), and pain worsened in 2 of 15 knees (13.3%). Conclusions In this small uncontrolled retrospective case series, GPS leukocyte-rich PRP injection was associated with improved NRS pain and KOOS quality of life at 1 year. These findings should be interpreted as preliminary observational associations and cannot establish treatment efficacy or safety. Larger prospective controlled studies with standardized PRP characterization are needed.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: